Skip to main content

Table 3 Factors associated with sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1-infected patients

From: Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients

 

Univariate analyses

Multivariate analyses

Odds ratio (95%CI)

P-value

Odds ratio (95%CI)

P-value

Age < 50 years

1.93 (1.10–3.38)

0.02

1.76 (0.71–4.37)

0.22

Female

1.26 (0.76–2.09)

0.37

  

BMI

1.02 (0.95–1.10)

0.51

  

Alcohol drinking

0.82 (0.46–1.46)

0.50

  

Diabetes Mellitus

0.78 (0.42–1.45)

0.44

  

HCV RNA (log IU/ml)

0.76 (0.55–1.07)

0.11

  

ALT

0.99 (0.99–1.00)

0.46

  

AST

0.99 (0.99–1.00)

0.44

  

Liver fibrosis stage 0–1

3.88 (1.83–8.20)

<0.001

5.00 (2.02–12.37)

<0.001

CYP27B1 rs10877012 CA/AA

1.67 (0.92–3.02)

0.09

1.24 (0.47–3.29)

0.67

DHCR7 rs12785878 GT/TT

1.93 (1.05–1.96)

0.032

2.69 (1.03–7.05)

0.04

  1. AST aspartate aminotransferase, ALT alanine aminotransferase, BMI body mass index, HCV RNA hepatitis C virus RNA, 95%CI 95% confidence interval